CHINA HEALTH GRP HD-10 (VNL1) - Total Assets
Based on the latest financial reports, CHINA HEALTH GRP HD-10 (VNL1) holds total assets worth €110.02 Million EUR (≈ $128.62 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore VNL1 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
CHINA HEALTH GRP HD-10 - Total Assets Trend (2021–2024)
This chart illustrates how CHINA HEALTH GRP HD-10's total assets have evolved over time, based on quarterly financial data. See net assets of CHINA HEALTH GRP HD-10 for net asset value and shareholders' equity analysis.
CHINA HEALTH GRP HD-10 - Asset Composition Analysis
Current Asset Composition (December 2024)
CHINA HEALTH GRP HD-10's total assets of €110.02 Million consist of 91.8% current assets and 8.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 14.1% |
| Accounts Receivable | €46.67 Million | 46.2% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how CHINA HEALTH GRP HD-10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VNL1 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CHINA HEALTH GRP HD-10's current assets represent 91.8% of total assets in 2024, a decrease from 99.2% in 2021.
- Cash Position: Cash and equivalents constituted 14.1% of total assets in 2024, up from 5.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 46.2% of total assets.
CHINA HEALTH GRP HD-10 Competitors by Total Assets
Key competitors of CHINA HEALTH GRP HD-10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Veracyte Inc
NASDAQ:VCYT
|
USA | $1.37 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Microba Life Sciences Ltd
AU:MAP
|
Australia | AU$43.35 Million |
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$49.04 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
India | Rs15.07 Billion |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.41 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
CHINA HEALTH GRP HD-10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.23 | 3.23 | 3.23 |
| Quick Ratio | 3.23 | 3.23 | 3.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €70.40 Million | €83.01 Million | €83.01 Million |
CHINA HEALTH GRP HD-10 - Advanced Valuation Insights
This section examines the relationship between CHINA HEALTH GRP HD-10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.50 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -15.4% |
| Total Assets | €100.96 Million |
| Market Capitalization | $1.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values CHINA HEALTH GRP HD-10's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: CHINA HEALTH GRP HD-10's assets decreased by 15.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CHINA HEALTH GRP HD-10 (2021–2024)
The table below shows the annual total assets of CHINA HEALTH GRP HD-10 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €100.96 Million ≈ $118.03 Million |
-15.41% |
| 2023-12-31 | €119.35 Million ≈ $139.53 Million |
-33.18% |
| 2022-12-31 | €178.62 Million ≈ $208.83 Million |
-8.08% |
| 2021-12-31 | €194.32 Million ≈ $227.19 Million |
-- |
About CHINA HEALTH GRP HD-10
China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People's Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research… Read more